Schonfeld Strategic Advisors 13F: Cuts ANIP Stake by $535K

Schonfeld Strategic Advisors Trims ANI Pharmaceuticals Position

Schonfeld Strategic Advisors dialed back its investment in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) during the most recent reporting period. According to its latest Form 13F filing with the Securities and Exchange Commission, the investment firm trimmed its position by 3.32%. The fund parted with 6,377 shares, ending the period with 185,629 shares of the drug manufacturer's stock.

The remaining holdings were valued at approximately $15.57 million at the end of the quarter. Investors should keep in mind that 13F filings are backward-looking documents that show what a fund held on the final day of the quarter, meaning Schonfeld may have adjusted its position since the filing date.

ANI Pharmaceuticals Stock Performance

On Saturday, ANI Pharmaceuticals shares were priced at $83.90. The stock has been trading in a 52-week range of $69.58 to $97.00. It is currently hovering above both its 50-day moving average of $76.33 and its 200-day moving average of $78.87. From a valuation perspective, the stock has a price-to-earnings ratio of 17.18 and a forward P/E ratio of 7.52.

Recent Earnings

ANI Pharmaceuticals reported strong top-line performance, bringing in total revenue of $978.38 million. That represents a revenue growth rate of 25.9% compared to the prior period. The company achieved an earnings per share of $4.59, backed by a net profit margin of 11.07% and a return on equity of 20.46%. Shareholders looking ahead can mark November 6, 2026, on their calendars, which is when the company is scheduled to release its next quarterly earnings report.

Insider Buying and Selling at ANI Pharmaceuticals, Inc.

While Schonfeld was paring its investment, some of the company's top executives were also reducing their personal holdings. On June 29, 2026, Senior Vice President and Chief Financial Officer Stephen Carey sold 2,850 shares at an average price of $84.12, bringing in $239,742. Earlier in the month, on June 12, 2026, Meredith Cook, the Senior Vice President and General Counsel, sold 500 shares at an average price of $82.03 for a total value of $41,015. Both executives executed these sales under pre-arranged Rule 10b5-1 trading plans, which schedule transactions automatically to avoid conflict-of-interest concerns.

Analysts Set New Price Targets

Several research firms have weighed in on ANI Pharmaceuticals recently. On September 23, 2026, Oppenheimer initiated coverage on the stock with a Perform rating and an $85.00 price target. Guggenheim maintained a Buy rating on August 10, 2026, though it trimmed its price target from $124.00 to $119.00, after previously reiterating its $124.00 target on July 10, 2026. Meanwhile, Canaccord Genuity has kept a Hold rating on the stock, setting a $90.00 price target on August 10, 2026, after initially launching coverage with a $91.00 target on July 17, 2026. Overall, the consensus among eight analyst opinions is a buy, with an average price target of $108.38.

About ANI Pharmaceuticals

ANI Pharmaceuticals develops, manufactures, and markets both branded and generic prescription drugs. The Baudette, Minnesota-based company focuses on niche products, including injectables, softgel capsules, and specialty therapies like Cortrophin gel. Keeping tabs on institutional movements and executive stock sales can help investors understand how the market views the company's growth prospects.

What to Watch

Investors interested in ANI Pharmaceuticals should watch for the upcoming quarterly earnings release on November 6, 2026, to see if the company's double-digit revenue growth continues. Future institutional filings will also reveal whether Schonfeld and other large funds continue to adjust their positions.